Among these seven validated hits, we further characterized the inhibitors targeting BTK (ibrutinib), STAT3 (niclosamide), and RTK (pazopanib), as previous studies have indicated the potential of these drugs to treat high-grade glioma [28,29,30,31]. Here, BTK is linked to glioma.